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Peptide-induced Conformational Changes in Class I 
Heavy Chains Alter Major Histocompatibility 
Complex Recognition 
By Jeffrey A. Bluestone,* Stephen Jameson,r Stephen Miller,$ 
and Robert Dick II* 
From the *Department of Pathology and the Committee on Immunology, Ben May Institute, 
University of Chicago, Chicago, Illinois 60637; the CDepartment of Immunology, University of 
Washington, Seattle, Washington 98195; and the SDepartment of Microbiology and Immunology, 
Northwestern University School of Medicine, Chicago, Illinois 60611 
Summary 
Small peptides, derived from endogenous proteins bind within the antigen binding groove created 
by the 3-pleated sheets and ol helices of the oll and o~2 domains of the class I molecule of the 
major histocompatibility complex (MHC). However, the precise role of peptide in class I MHC 
conformation remains unclear. Here, we have shown that, in at least some instances, changes 
induced in the MHC molecule by the binding of distinct peptides can be identified as specific 
alterations in serological epitopes expressed on the class I protein. The nature of specific peptides 
expressed by dass I-bearing cells may, therefore, have a dramatic influence on T cell development, 
self-tolerance, and alloreactivity. 
I n recent years, tremendous progress has been made in 9 elucidating the molecular aspects of MHC class I-peptide 
interaction. The structural nalyses of crystallized HLA class 
I molecules have included A2, Aw68, and B27 (1-3). In all 
instances, mall peptides have been observed within the cleft 
formed by the ol helices and ~-pleated sheet constituted by 
the c~1 and ol2 domains. Recent studies have shown that op- 
timal peptide binding to the murine class I antigen, H-2K b, 
occurs with small peptides (8-9) amino acids long, peptides 
containing a leucine at the COOH terminus, and amino acids 
with aromatic side chains (phenylalanine or tyrosine) at the 
5 th (8 mer) or 6 th (9 met) position (4-6). These amino acid 
residues provide the anchor points for the peptide in the cleft. 
The recent solution of the x-ray crystal structure of a single 
MHC class I molecule, H-2K b, occupied by distinct pep- 
tides, suggested that these peptides may influence MHC 
dass I conformation (7). 
We, therefore, xamined the role of peptide in MHC con- 
formation using the mutant cell lines RMA-S and T2. These 
cell lines are class I-deficient somatic variants of RMA (mouse) 
and B-LCL721 (human) tumor cells due to defects in the trans- 
porter proteins, transporter associated with antigen processing 
(TAP), necessary for providing processed peptides for binding 
to the newly synthesized class I molecules (8-12). The addi- 
tion of preprocessed antigenic peptides to these mutant cells 
results in stable assembly and cell surface xpression of class I 
predominantly bound to the added peptide. 
In the present experiments, we studied the effects of specific 
peptides on class I recognition of H-2Kb-specific alloanti- 
bodies. The peptide transporter mutants, RMA-S and T2- 
Kb/D a, were pulsed with various K b binding peptides. Class 
I molecules bound by the different peptides were distinguish- 
able by mAb binding. These results uggest that, in at least 
some instances, MHC conformation as detected by serolog- 
ical epitopes may depend on the peptide bound to the class 
I molecule. 
Materials and Methods 
Tumors. The Rauscher virus-transformed lymphoma cells, RMA 
and RMA-S (13), were a gift from Dr. K. K~rre (Karolinska Insti- 
tute, Stockholm, Sweden). The human T cell lymphomas, C1R 
and B-LCL721.174 x CEM, (T2 [14]), were the kind gift of Dr. 
P. Cresswell (Yale University, New Haven, CT). The T2 cells were 
transfected with a chimeric MHC class I gene, Kb/D b (i.e., exons 
2 and 3 encoding the cr and c~2 domains of K b ligated to exon 
4 encoding the oe3 domain of Dd; kindly provided by Dr. T. Potter 
(National Jewish Hospital, Denver, CO) by electroporation. 
Peptide Preparation and Binding Assays. The majority of the pep- 
tides were prepared by solid-phase t chniques using the F-moc 
method, or by the University of Chicago Peptide Synthesis Labo- 
ratory by the T-boo method, and analyzed by HPLC for purity. 
Amino acid analyses were performed to assure appropriate amino 
acid composition. The peptides used in the present s udies included: 
OVA 257-264 (SIINFEKL [15]); influenza nucleoprotein 1968 (FLU 
NP) 345-360 (SFIRGTKVSPRGKLST [16]); vesicular stomatitis 
virus nucleoprotein (VSV NP) 52-59 (RGYVYQGL [17]); and 
Sendai virus nucleoprotein 322-330 (APGNYPAL; SV8 NP) or 321- 
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330 (FAPGNYPAL; SV9 NP) (18). In peptide-pulsing experiments, 
tumor cells at a concentration of 5 x 10S/ml, were incubated 
overnight at 37~ with individual peptides (100/zg/ml) before assay. 
mA~ The MHC H-2Kb-specific mAbs used were as follows: 
5F1-2-14 (c~2 [19]); EH-144 (c~1 [20]); AF6-88.5 (21); 100-30 (22); 
and Y-3 (23). In addition, the c~3-specific, H-2D d mAb, 34-2-12 
(24), were used in some xperiments a a means to determine abso- 
lute levels of the product of the exon-shufl~ed H-2Kb/D a gene. 
Cell surface xpression of H-2K b was studied by flow cytometry 
using a FACScan | (Becton Dickinson Immunocytometry S stems, 
Mountain View, CA). 
Results and Discussion 
To assess class I conformational features, the binding of 
a panel of mAbs specific for H-2K b was examined on wild- 
type, RMA, and mutant, RMA-S tumor lines in the absence 
or presence of distinct exogenous peptides. As seen in Fig. 
1, four anti-H-2K b mAbs reacted with the wild-type RMA 
cells whereas RMA-S cells, when incubated at 37~ expressed 
little H-2K b. In contrast, overnight incubation of RMA-S 
at room temperature upregulated Kb expression (right). 
However, examination of the relative binding of the different 
mAbs to RMA-S RT revealed that 100-30 bound propor- 
tionally greater than 5F1-2-14 or Y-3, a serological pattern 
different from that seen on RMA. 
The serological profile of K s molecules on RMA-S pulsed 
with exogenous peptides was also significantly different han 
RMA. The serology of RMA-S cells pulsed with SV8 NP, 
SV9 NP, and FLU-NP peptides was similar to the RMA-S 
RT cells as 5F1-2-14 bound relatively poorly, if at all (SV9 
NP), to these cells, and 100-30 reacted strongly. In contrast, 
K b molecules expressed by RMA-S cells incubated with the 
OVA peptide or VSV NP peptide reacted strongly with the 
5F1-2-14 mAb. In addition, there was virtually no binding 
of the 100-30 mAb to OVA-pulsed RMA-S cells and weak 
binding to VSV NP-pulsed RMA-S. The relative differences 
in the K b reactivity were not due to antibody titer or iso- 
type, as shown in Fig. 2. All of the antibodies bound at 
different saturating levels on each cell type. For instance, pla- 
teau binding of 5F1-2-14 occurred with a mean fluorescence 
(MF) of 325 on OVA-pulsed RMA-S cells, but only MF 50 
on SV8 NP-pulsed RMA-S. In contrast, 100-30 bound with 
a MF of 125 and 15 on SV8 NP- and OVA-pulsed RMA-S 
cells, respectively. The differences in maximal antibody bind- 
ing, combined with the dramatically different slopes of the 
titration curves, suggested that the same mAb has different 
a~nities for the K s molecule associated with different pep- 
tides. It is interesting that another mAb, AF6-88.5, whose 
K b binding was previously reported to be murine/32M de- 
pendent (25), and did not react with human/32M-associated 
human C1R-K b cells (data not shown), also demonstrated 
different binding activity on K b molecules loaded with the 
different peptides. RMA-S cells pulsed with OVA, VSV NP, 
and SV9 NP bound AF6-88.5 well, whereas RMA-S RT, 
RMA-S plus SV8 NP, and RMA-S FLU-NP (data not shown) 
bound it poorly. Therefore, it is likely that the AF6-88.5 
binding is dependent on both murine/32M association and 
peptide-induced class I conformation, perhaps at the site where 
B2M interacts with the or1 domain of K b (26). 
To determine the absolute binding of the Kb-specific 
mAbs, T2 cells were transfected with a chimeric Kb/D a con- 
struct encoding the c~1 and o~2 domains of K s and the c~3 
domain of D d. This chimeric MHC molecule can be 
identified by an c~3-specific mAb, 34-2-12, that is not 
influenced by peptide binding. As seen in Fig. 3 a, the pat- 
tern of mAb binding varied significantly among the peptide- 
pulsed T2-Kb/D a tumor lines. Anti-H-2D d binding in- 
creased equivalently on transfectants pulsed with SV9 and 
OVA peptides (dashed lines). Furthermore, there was a dra- 
matic difference in the reactivity of 5F1 (solid lines) and 100- 
30 (dotted lines) between the two peptide-pulsed cell popula- 
tions. Similar dramatic differences were observed when K b- 
specific mAb reactivity was normalized to the ot3-specific mAb 
staining (Fig. 3 b). Two conclusions can be drawn from this 
data. First, the staining of peptide-pulsed Kb/Da-transfected 
T2 cells was remarkably similar to the RMA-S cells cultured 
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Figure 1. Serological nalysis of peptide-pulsed RMA-S cells. Tumor ,~ vsoo ,11~soo 
cells, pulsed overnight with individual peptides (100/zg/ml), were incubated 
for 30 min with saturating amounts of mAb followed by counterstaining 
reagent. Flow cytometry analyses were performed on 10,000 cells gated 
by size and propidium iodide exclusion to eliminate dead cells. Data is 
shown as the mean log fluorescence of the cell population. 
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Figure 2. Titration of mAbs on peptide-pulsed RMA-S cells. Peptide 
pulsing of RMA-S cells was performed as in Fig. 1. Various dilutions of 
mAb were added and binding assessed asabove. 
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Figure 3. Serological analyses of peptide-pulsed T2-Kb/D a cells. (a) 
FCM analyses were performed as in Fig. 2 on T2-Kb/I~ cells pulsed with 
individual peptides overnight. Data is depicted as histograms of 10,000 
cells. Background staining with FITC-coupled anti-mouse Ig is shown 
(spread ots). Cells were stained with 5F1-2-14 (solid lines), 100-30 (dotted 
lines), and 34-4-12 (anti-D a, dashed lines). (b) Kb/D a staining ratios were 
determined by dividing the maximal mean log fluorescence of the individual 
anti-K bmAbs by the maximal mean log fluorescence of the c~3-spedfic, 
anti-I~ mAb, 34-2-12. In this experiment, 34-2-12 stained unpulsed 
T2-K b with a mean log fluorescence of 500, whereas the mean fluores- 
cence of peptide-pulsed K b ranged from 1,300 to 1,500. 
with the different peptides. For instance, the absolute binding 
of 5F1-2-14 was much more ef~dent on OVA-pulsed cells 
than on SV9 NP cells. In contrast, 100-30 did not bind OVA- 
pulsed cells at all, but bound very well to SV9 NP-pulsed 
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Figure 4. Titration of OVA peptide T2-Kb/D d. (a) T2-Kb/D d tumor 
cells were incubated overnight with varying concentrations of peptide, 
washed and analyzed using different mAbs including 5F1-2-14, 100-30, 
and 34-2-12. Kb/D d staining ratios were determined by dividing the max- 
imal mean log fluorescence of the individual anti-K bmAbs by the max- 
imal mean log fluorescence of the ol3-specific, anti-D dmAb, 34-2-12 as 
above. (b) Flow cytometry analysis of RMA-S cells pulsed with mutated 
OVA peptides. Individual amino acid numbers represent the alanine- 
substituted residue in the OVA peptide. Cells were incubated overnight 
with saturating amounts of peptide, mAb staining of peptide-pulsed cells 
is depicted as mean log fluorescence. 
cells. In fact, these serological lterations were observed in 
as little as 1-h incubation with peptide (data not shown). 
Second, recent studies have shown that the nonamer peptide 
of the Sendai NP binds 1,000-fold better than the octamer. 
Yet, with the exception of 5F1-2-14 binding, which was weak 
on SV8 NP-pulsed RMA-S but nonexistent on SV9 NP-pulsed 
cells, the mAb binding pattern observed with SV9 and SV8 
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NP was similar, whereas mAb-binding to SV8 NP- and OVA- 
pulsed cells was quite dissimilar. Thus, the differences in se- 
rology of the K b molecule loaded with different peptides did 
not correlate with peptide length or affinity. 
A dose titration of OVA peptide on T2-Kb/D d showed 
that overnight incubation with as little as 10-3-10 -4/~g/ml 
of OVA peptide resulted in a diminution of 100-30 mAb 
binding and a concomitant increase in 5F1-2-14 binding (Fig. 
4 a). A more detailed analysis of the influence of the OVA 
peptide on K b serology was performed using OVA peptides 
in which individual amino acids were substituted with ala- 
nine residues. As illustrated in Fig. 4 b, OVA peptides con- 
taining substituted alanines at positions 261 or 264 did not 
increase Kb expression. In previous tudies by Falk et al. (4, 
27), residues 5 (amino acid 261) and 8 (amino acid 264) were 
shown to be critical residues for peptide binding to K b. 
Thus, it is not surprising that these alanine substitutions 
affected MHC binding. In contrast, significant increases in 
H-2K b expression was observed with all other alanine- 
substituted peptides. The reactivity of four different mAbs 
on OVA-pulsed RMA-S cells was not significantly effected 
by several individual alanine substitutions including: OVA 
peptide-serine 257 --* alanine 257 (OVA-S257A), OVA-I258A, 
OVA-N260A, or OVA-E262A. However, substitution of the 
isoleucine 259 with an alanine resulted in diminished AF6.88-5 
staining and increased 100-30 staining. Residue 259 is thought 
to be an MHC contact residue (5, 7). Therefore, substitu- 
tion of an isoleucine with an alanine may alter peptide-MHC 
contact. 
One implication of the serological nalysis of the alanine- 
substituted peptide is that, in addition to direct effects of pep- 
tide binding, there may be allosteric effects as well. Several 
years ago, in collaboration with Ajitkumar et al., we demon- 
strated that single point mutations in amino acids 162 or 166 
of the oc2 domain had profound effects on the 5F1-2-14 epi- 
tope (28). Based on recent crystal structure analyses, the 
NH2-terminal residues of the peptide localize near these 
amino acids. These observations suggest hat many of the 
serological changes observed using different peptides depend 
on the NHz-terminal residues of the peptide which vary 
substantially among OVA, VSV NP, and SV NP. In fact, the 
difference in 5F1-2-14 binding between SV8 NP and SV9 NP 
is a direct result of the NH2-terminal phenylalanine. How- 
ever, we also observed that a single amino acid change in res- 
idue 7 of the OVA peptide (OVA-K263A) decreased 5F1-2-14 
binding (Fig. 4 b), suggesting possible aUosteric effects on 
mAb binding. 
In conclusion, the data cannot easily distinguish whether 
the serological changes observed result solely from confor- 
mational changes in the ce helices or associated side chains, 
or from the steric effects ofpeptide binding. The 100-30 and 
5F1-2-14 epitopes have totally distinct patterns of binding. 
This does not appear to be a steric effect of peptide binding 
since 5F1-2-14 does not effectively bind to "empty" K b mol- 
ecules (Fig. 3). By comparison, the 100-30 mAb binds effec- 
tively to empty K b and SV-pulsed K b, but not OVA-pulsed 
K b. More importantly, recent x-ray crystallographic studies 
by Fremont et al. (7) illustrate the potential conformation 
changes that result from the binding of different peptides to 
the same MHC class I molecule. 
Finally, the likelihood that class I MHC molecules can exist 
in different conformations on the cell surface has profound 
implications for aUorecognition. Although a number of studies 
have suggested that many aUoreactive c lls are peptide specific, 
recent studies by several groups support he idea that some 
alloreactive clones recognize MHC conformational epitopes, 
since some of the alloreactive CTL examined recognized pep- 
tides present in several distinct peptide peaks after HPLC sepa- 
ration of peptides eluted from class I MHC, "naked" MHC 
(29, 30), or class I loaded with distinct peptides (31; and Blue- 
stone, J. A., S. Jameson, K. Arunan, and R. Dick II, manu- 
script in preparation). These results upport he notion that 
at least some alloreactive T cells recognize class I in a peptide- 
dependent but not peptide-specific manner, and that the na- 
ture of the peptide that occupies the MHC groove can alter 
allorecognition of foreign class I MHC. If, indeed, the na- 
ture of the peptide within the MHC cleft can influence TCR 
recognition, then subtle peptide-driven changes in MHC struc- 
ture would impact not only on antigen-specific responses, 
but also on T cell development, self-tolerance totissue-specific 
antigens, and alloreactivity. 
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